Table 1.
Patient with FL Pathologic and clinical data
| FL sample number | Pathologic diagnosis | Previous Tx | Time from Tx to Bx, mo |
|---|---|---|---|
| FL1 | FLg2 (30% g3A) | R-CVP | 1 |
| FL2 | FLg3 (mostly 3B) | R-CHOP, ASCT | 36 |
| FL3 | FLg1 | None | |
| FL4 | FLg2 (focal g3) | None | |
| FL5 | FLg2 | None | |
| FL6 | FL and diffuse g2 | None | |
| FL7 | FLg2 | None | |
| FL8 | FLg3b and diffuse | None | |
| FL9 | FLg1 | None | |
| FL10 | FLg2 | Radiation | Bx not in prior XRT field |
| FL11 | FLg1 (focal g2) | R-CHOP, 131I | 39 |
| FL12 | FLg3B (focal g2) | R-CHOP, R-ICE, ASCT | 16 |
| FL13 | FLg3a | None | |
| FL14 | FLg1 | None | |
| FL15 | FLg2 | None | |
| FL16 | FLg1 | R-CHOP, R | 24 since chemo; 2 since R |
| FL17 | FLg2 | None | R and IFN for hepatitis C 24 before Bx |
| FL18 | FLg1 | None | |
| FL19 | FLg2 | None | |
| FL20 | FLg1 | None | |
| FL21 | FLg1 | None | |
| FL22 | FLg1 | None | |
| FL23 | FLg2 | N/A | |
| FL24 | FLg2 | R-CHOP/methotrexate, R | 3 |
| FL25 | FLg1 | NA | |
| FL26 | FLg1 | None |
Tx indicates treatment; Bx, biopsy; g, grade; R, rituximab; CVP, cyclophosphamide, vincristine, prednisone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; ASCT, autologous stem cell transplantation; ICE, ifosfamide, carboplatin, etoposide; XRT, radiation; and 131I, iodine (131I) tositumomab.